Heart and Vascular Care

The following list contains clinical studies in which the OSF HealthCare Cardiovascular Institute is enrolling patients.

For questions or to enroll, please contact our research staff at (309) 589-1930 in the Peoria area and (815) 395-9181 in Rockford.

Currently Enrolling - Peoria Area

  • ANCHOR - Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry
  • Summary: A registry intended to expand the clinical knowledge base on the use of the Aptus™ Heli-FX™ EndoAnchor™ System by including “real world” use over a broad spectrum of geographies, by a wide variety of practicing clinicians, and with a minimal degree of subject selection criteria.

    Investigator: Dale Mueller

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • PULSE PAH - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) versus Placebo in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH)
  • Summary: A randomized clinical study to determine efficacy, safety and tolerability of pulsed, inhaled Nitric Oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial hypertension. 

    Investigator: Chetan Bhardwaj

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02725372

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • STEP Pilot Study - A Supervised TAVR Exercise Program (STEP) for Patients Prior to Undergoing Transcatheter Aortic Valve Replacement: A Pilot Study.
  • Summary: A Supervised TAVR Exercise Program (STEP) for patients prior to undergoing Transcatheter Aortic Valve Replacement.

    Investigator: Jay Patel

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02766075

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • UPSTREAM - Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome: An ED-Based Clinical Registry
  • Summary: An ED-Based clinical registry evaluating the utilization of Ticagrelor in the upstream setting for Non-ST-Segment Elevation Acute Coronary Syndrome.

    Investigator: Sudhir Mungee

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02271022

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • DAPA HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction
  • Summary: A study to evaluate the effect of Dapagliflozin on the incidence of worsening Heart Failure or Cardiovascular Death in patients with chronic Heart Failure with reduced Ejection Fraction.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03036124

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • PIONEER HF - A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF)
  • Summary: A study to evaluate the effect of Entresto versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of Entresto compared to enalapril in Heart Failure patients with reduced Ejection Fraction who have been stabilized following hospitalization for acute decompensated Heart Failure.

    Investigator: Chetan Bhardwaj

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02554890

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • PRESERVED HF - Effects of dapagliflozin on biomarkers, symptoms and functional status in patients with Type 2 diabetes or pre-diabetes, and PRESERVED ejection fraction Heart Failure
  • Summary: A study to evaluate the effects of Dapagliflozin on biomarkers, symptoms and functional status in patients with Type II Diabetes or pre-diabetes, and preserved Ejection Fraction Heart Failure.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03030235

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • VICTORIA - A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction
  • Summary: A study to evaluate the efficacy and safety of the oral sGC stimulator Vericiguat in subjects with Heart Failure with reduced Ejection Fraction.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02861534

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

Currently Enrolling - Rockford Area

Peripheral Artery Disease (PAD)

  • GORE ISR 14-04 - Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
  • Summary: A Clinical trial for patients who have already had stents in the legs and are experiencing reoccurring symptoms of PAD.

    Investigator: Jan Skowronski

    Location: OSF HealthCare Cardiovascular Institute, Rockford, Illinois

    ClinicalTrials.gov: NCT02542267

    Contact: Joanne Carner, (815) 395-9181, joanne.e.carner@osfhealthcare.org
  • PRESERVE II - Clinical Study to Evaluate the Safety and Effectiveness of the Zenith®Branch Endovascular Graft-Ililac Bifurcation (PRESERVE-Zenith®Iliac Branch)
  • Summary: A Clinical trial for patients with an iliac aneurysm needing treatment.

    Investigator: David Cable

    Location: OSF HealthCare Cardiovascular Institute, Rockford, Illinois

    ClinicalTrials.gov: NCT02571907

    Contact: Lindsey Tompkins, (815) 395-9181, lindsey.a.tompkins@osfhealthcare.org

Arrhythmia/Devices

  • DEEP - Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation
  • Summary: A Clinical trial for patients with long standing Atrial Fibrillation that is now symptomatic.

    Investigator: Farhad Farokhi

    Location: OSF HealthCare Cardiovascular Institute, Rockford, Illinois

    ClinicalTrials.gov: NCT02393885

    Contact: Melissa Magnuson, (815) 395-9181, melissa.c.magnuson@osfhealthcare.org

Follow-Up Only - Peoria Area

  • IMPERIAL - A randomIzed trial coMParing the ELUVIA™ dRug-elutIng stent versus Zilver® PTX® stent for treatment of superficiAL femoral and/or proximal popliteal arteries
  • Summary: A randomized trial comparing the ELUVIA™ drug-elutIng stent versus Zilver® PTX® stent for treatment of superficial femoral and/or proximal popliteal arteries.

    Investigator: John Rashid

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • REVEAL - Randomized EValuation of the Effects of Anacetrapib through Lipid-modification: A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease
  • Summary: A trial to evaluate the effects of anacetrapib among people with established vascular disease.

    Investigator: Tinoy Kizhakekuttu

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309 589-1937, rita.j.klundt@osfhealthcare.org
  • ABSORB III - Randomized Controlled Trial - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions
  • Summary: A randomized, controlled trial to Evaluate the Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of subjects with de novo native coronary artery lesions.

    Investigator: Sudhir Mungee

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • EXCEL - Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
  • Summary: Evaluation of XIENCE versus Coronary Artery Bypass Surgery for effectiveness of left main revascularization.

    Investigator: John Rashid

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  • Summary: A randomized study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced an Acute Coronary Syndrome.

    Investigator: Keattiyoat Wattanakit

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • OVATION PAS - A PMA Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
  • Summary: A post-PMA approval, prospective, consecutively enrolling, nonrandomized multi-center clinical study to evaluate the safety and effectiveness of the Ovation/Ovation Prime Abdominal Stent Graft System through five years of implantation.

    Investigator: Ryan Nolte

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • QUAD PAS - Quadripolar Pacing Post Approval Study
  • Summary: A post approval study evaluating the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy.

    Investigator: Joseph Sarmiento

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org
  • SJM CLAS - St. Jude Medical Cardiac Lead Assessment Study
  • Summary: A post market study to determine the prevalence and incidence of externalized conductors and other visual lead anomalies (as evidenced by imaging) and the risk of progression to electrical dysfunction in a large series of ICD/ CRT-D/CRT-P devices containing one or more of the following SJM leads: Riata leads, Riata ST silicone leads, Durata leads, QuickSite/QuickFlex CRT leads.

    Investigator: Joseph Sarmiento

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org
  • THEMIS - A Multinational, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus
  • Summary: A Randomized trial to evaluate the effect of Ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in Patients with Type 2 Diabetes Mellitus.

    Investigator: Tinoy Kizhakekuttu

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org